Zepp Health FY26 Q2 net loss widens to US$11.3 million; revenue rises 6.9% to US$63.5 million - ZEPP News | RalliesZepp Health FY26 Q2 net loss widens to US$11.3 million; revenue rises 6.9% to US$63.5 million
Z
ZEPP• Outlook and pricing plans
- Zepp guided Q3 2026 revenue at US$68 million to US$73 million.
- The company also plans Bip family price increases starting January 2027.
Q2 revenue and loss widen
- Zepp posted Q2 2026 revenue of US$63.5 million, up 6.9% from a year earlier.
- Net loss attributable to shareholders widened to US$11.3 million; loss per ADS deepened to US$0.72 on a GAAP basis.
Margins and cash position improve
- Gross margin rose to 37.4%, up 1.2 percentage points year over year, driven by a more favorable product mix.
- Cash, cash equivalents and restricted cash totaled US$106.3 million at June 30, 2026, reflecting improved working-capital management.
•
